{
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "妇女患有 claustrophobia 和 IBS 或不符合初级试验或次级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3
        ],
        "Secondary_evidence_index": [
            2,
            9
        ]
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "没有心理健康,体重,肿瘤大小,卡诺夫斯基/ECOG分数或预期寿命的条件需要满足,以获得初级试验的资格",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "二级试验要求患者超过一定年龄,但初级试验不指定参与的年龄范围。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "目前参加二级试验的患者不能同时参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2 + 主要试验中的患者在整个试验期间接受了与二次试验小组 2 中的患者相同的Trastuzumab剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "在初级试验或次级试验的AES中没有记录过贫血、低温或幻觉的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "一个在过去一个月内接受器官移植的患者,并且仍然躺在床上,将被排除在初级试验中,但可能有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "任何对 cefalosporin 或 trimetoprim/sulfamethoxazole 过敏的患者都不能参加二级试验,对 levofloxacin 或 celecoxib 过敏的患者也将被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "初级试验中的干预通过不同的途径进行管理。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "患有新诊断的第四阶段乳腺癌的妇女,确认为ER+考虑进行乳房切除,有资格参加初级试验和次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "具有 histologically 确认的第 4 阶段乳腺癌的患者是 ER 阳性,PR 阳性或 HER2/neu 负的,有资格参加二次试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4
        ]
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "二级试验和初级试验的结果包含完全不同的结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验参与者没有接种任何疫苗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "初级试验的 A 和 B 同一 三个 LD V934 电孔注射",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "二级试验和初级试验在其结果中使用不同的衡量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "与初级试验中的组的结果没有显著差异,反射学组和次级试验的控制组产生了相同的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "在TAK-228 Plus治疗的初级试验中,6周以上的Tamoxifen治疗患者发现基67表达率的细胞百分比减少了5%",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "初级试验的手臂2的操作时间比手臂1更高,因此手术内乳腺检查在这方面比标准乳腺检查做得更好。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "有几种不同的心脏相关AE的例子记录在初级试验的队列1",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9,
            10,
            11
        ]
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "初级试验和次级试验的患者经历了疮事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "干预1在初级试验中,并在次级试验中的所有干预药物必须注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级试验中,有10倍的肝毒性病例,因为有高血压和胰腺切除症的病例",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "只有有限的自我照顾能力的候选人;被限制在床上或椅子上超过50%的清醒时间可以参加初级和次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "初级试验的1号团体没有报告任何AES,但几乎所有2号团体候选人至少受过1次AES。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "在过去2周内接受化疗或放射治疗的患者,患有不稳定的喉咙痛,或患有2级以上神经病的患者不能参加二级试验,但仍然可以参加初级试验,除非他们有非愈合的外科伤口。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            14,
            15,
            23,
            24,
            27
        ]
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "二级试验候选人必须满足某些绩效状态条件才能参加,而这不需要被接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "冠状动脉硬化是初级试验中记录的最常见的AE",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "初级试验的干预包括一个药物,而次级试验的干预需要至少3种不同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "患有前期痴呆症或混合痴呆症的患者有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ]
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "初级试验的两组包含了相同数量的参与者",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            13
        ]
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "患有肺病史且目前有乳房植入物的患者不能参加二级试验或初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            20
        ],
        "Secondary_evidence_index": [
            12
        ]
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "总体不良事件在初级试验中少于二级试验,但在初级试验中心脏病发作/心脏病发作的病例多于二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "初级试验的患者需要在研究的第8天接受一次注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "初级试验的2组接受了 0.5ug / kg的肌痛(5ml),二级试验群体的患者没有收到任何肌痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "诊断 2-3 脑转移将导致排除从二级试验,但这种诊断的患者仍然可能有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            13
        ]
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "被诊断出患有 Leptomeningeal 癌症的患者不符合初级试验的条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "在过去一年内以前服用加巴宾丁或赫塞普丁的治疗,将导致排除在二级试验中,但不会排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            18
        ],
        "Secondary_evidence_index": [
            12,
            13
        ]
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "在初级试验中, placebo 干预和 Memantine 干预都被口服,每日一次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "基于CBT的治疗对初级试验候选人是禁止的,但他们仍然可能有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            31
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/7的初级试验参与者,和0/1674的二级试验参与者遭受AE。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "初级试验的群体 2 是通过口服注射的,而群体 1 是通过 IV 接收的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "在过去3年内患有肺症的患者被排除在初级试验中,但根据研究人员的决定可能有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "在初级试验的两组患者中,超过三分之一的患者在大约7个月的研究后,在乳房和轴心淋巴结中出现了病理完整反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "初级试验的手臂2的运行时间比手臂1更高,因此控制组在这方面表现得比测试组更好。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "在试验期间的几个时刻,初级试验中的患者接受与二级试验组2中的患者相同的Trastuzumab剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "只有三种不同类型的不良事件在初级试验中影响患者,胰腺炎,胆症,肝疼痛和发烧中微波尼亚",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "初级试验中至少有一名患者经历了几次不同不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "针灸 初级试验中的患者在他们的淋巴肿瘤中发生了更好的变化,而不是与丸激素霜服用的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "在二级试验中观察到的唯一类型的Aes是眼部肿瘤,上肠道出血和胸部疼痛,在初级试验中没有Aes记录。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "初级试验的群体1被投放PR负,ER负和HER-而群体2接收HER2+",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "在初级试验中,用于这两种干预措施的激光辅助荧光膜。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "2、73 名初级试验参与者和 0/1674 名次级试验参与者患有急性心脏病发作",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "初级试验是评估患有治疗相关不良事件的患者数量,而次级试验测量其患者的平均睡眠时间为分钟。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "只有初级试验的1组将观看教育DVD作为干预的一部分,而2组则将接受定期的放射治疗剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "初级试验使用1个月的周期进行干预,而次级试验则没有周期性治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "正在考虑人工智能疗法的被诊断为本地导体癌症的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "每个参与者在初级试验中接受相同的干预,无论他们是否患有癌症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级试验的两组都以相同的频率在整个试验中服用相同的剂量Docetaxel,Doxorubicin和Cyclophosphamide,但2组包括这些特定药物的三个额外治疗周期。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "在初级试验和次级试验中,有几个不良事件发生在30%以上的参与者中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "饮食障碍在初级试验候选人中并不常见",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7
        ]
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "只有特定国籍的女性患者才能参加初级试验,参加二级试验不需要这种条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67
        ]
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "主要试验干预包括使用TheraSpheres的放射性胚胎化,另一方面,次要试验干预是基于ibrutinib和MEDI4736。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "初级试验和次级试验共记录了0起不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "在初级和次级试验中,超过15%的患者在研究期间患有感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            11
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "脑骨内 2-3 个脑转移的诊断将导致排除在次期试验中,但这种诊断的患者仍然可以选择进行初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            1,
            2
        ],
        "Secondary_evidence_index": [
            13
        ]
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "二级试验中最常见的不良事件是贫血,影响超过5%的患者,初级试验中没有记录AE。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "初级试验中的几名患者在研究的10周内没有任何疼痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "任何具有重大或不受控制心血管功能障碍的患者都不能参加初级或次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "被诊断为 in situ 恶性管道癌的患者有资格参加二级试验,但被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "所有在初级试验中接受安慰剂干预的患者都经历了",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10,
            11,
            6,
            7,
            8,
            15
        ]
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "任何被诊断为癫痫、症综合征或贫血的癌症患者都不能符合初级和次级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "几个初级试验候选人每天服用1000微克塔拉索帕里布,作为干预的一部分。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "初级试验的1号和2号小组接受相同的CUDC101剂量,但1号小组更常服用CUDC101。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "初级试验使用3周的周期进行干预,而次级试验则没有周期性治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "每个初级试验的患者在放射疗法期间接受100至1600μg的芬太尼下语言喷雾剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "在初级试验中有更多的感染、不对称和恶心病例,而不是二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "患有4级癌症的患者有资格参加二级试验和初级试验,如果他们提供知情同意。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "初级试验和次级试验都使用pCR作为其结果测量,初级试验的两个群体之间的结果差异很小,而在次级试验中,Arm 2比Arm 1有更好的结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "除了1名在初级试验中接受Sunitinib + Docetaxel + Trastuzumab治疗的患者之外,所有患者都经历了治疗紧急不良事件,不到一半的患者经历了严重的治疗紧急不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "二级试验和初级试验报告的结果使用相同的衡量单位。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "初级试验和次级试验在他们的群体中记录了超过100个总不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "初级试验中的安慰剂和Trabectedin干预都通过每两周进行3小时的静脉注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "患有4级癌症的患者不符合二级试验的条件,但他们有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "初级试验的群体2被作为群体1的群体2服用了两倍的剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "在过去2周内接受化疗或放射治疗的患者,患有不稳定的喉咙痛,或患有2级以上神经病的患者不能参加二级试验,但如果他们满足所有相关的纳入标准,仍然可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            14,
            15,
            23,
            24,
            27
        ]
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "在初级试验中记录的任何个别不良事件类型都没有影响超过一个患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "患者可能在过去6个月内没有腹部结膜、胃肠道穿孔、更年期后腺癌、中风、过渡性结核发作、内腹部断层或显著精神疾病的历史,如果他们想参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            11,
            19,
            1
        ]
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "18岁或以上的女性有资格参加二级审判和初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "总共 35 名在初级试验中接受 Sunitinib + Docetaxel + Trastuzumab 治疗的患者经历了治疗紧急不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "初级试验中的任何患者都没有经历10周内可想象的最糟糕的疼痛。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "二级试验的患者比初级试验的患者更频繁地患有贫血、肺炎和焦虑症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "初级试验中的一名患者发生了手术切割在手术后重新打开的事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "初级试验中的 AZD0530 175 mg 组在 4 周时表现出比 Zoledronic Acid 4 mg 组更显著的 betaCTX 百分比变化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "少于10%的初级试验参与者在经过几个月的高剂量化疗后,出现了循环肿瘤细胞的减少。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "在初级试验中,只有一个群体每天服用阿尔莫达菲尼尔,而在次级试验中,所有患者都服用相同的PDR001剂量,但MCS110的剂量不同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "初级试验的结果表明,在手术前7天和乳腺癌手术后14天,每日20mg的塔莫西芬平均减少了40%的肿瘤的Ki67表达。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "CAPECITABINE 每日口服,每位患者在初级试验的第 2 组的第 1 周期 21 天。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "与初级试验不同,患者必须诊断出下列基因之一的突变; PTEN,BRAF,KRAS,NRAS,PI3KCA,ErbB1,ErbB2,MET,RET,c-KIT,GNAQ或GNA11被纳入次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "在初级试验的群体2中记录了更多的心跳、心脏散发和腹部疼痛,而不是二级试验的群体1中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "初级试验中至少记录了1次胃肠不良事件和2次或以上的精神病事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "初级试验使用Lenalidomide的剂量较介入1中的次级试验使用Lapatinib的剂量高,初级试验的干预持续时间较长。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "在初级试验中记录的所有Aes发生在1群患者中",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "初级试验中的患者没有与二级试验中的患者相同的副作用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "在初级试验中,每天只有一群人服用阿尔莫达菲尼尔,而在次级试验中,所有患者都服用相同的100毫克PDR001剂量和1毫克MCS110剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "二级试验中观察到的不良事件比初级试验多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "二级试验和初级试验使用相同的结果测量;乳房内PCR患者的比例,定义为在完成化疗后进行手术时在乳房中没有残留侵入性肿瘤的证据",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "我们无法比较初级试验和次级试验中的不良事件,因为它们似乎没有记录在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "二级试验或初级试验都没有测量肿瘤中Ki67表达的变化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13%的PR+初级乳腺癌的初级试验参与者接受了HER2靶向的PET/CT治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "初级试验2组的患者比二级试验1组的患者,在接受Empegfilgrastim的剂量较低的情况下,显著少患中性衰退。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "低血病患者被排除在初级试验中,但高血病患者可能有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "初级试验干预是口服的,而次级试验干预是通过注入静脉的针或管进行的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "非洲裔美国患者可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "患有肿瘤脑膜炎的患者可能有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "主要试验1组中的大多数患者在干预后进行筛查,无论癌症类型如何。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "初审和次审进行口头讲话。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "对不同干预措施的MTD的初级试验和次级试验报告,二级试验中患者的MM-111的MTD为每日15mg",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "乳腺癌和卵巢/腹腔癌患者在初级试验中接受了相同的干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "初级试验的1组患者接受的Eribulin剂量高于2组患者接受的Docetaxel。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "二级试验的患者比初级试验的患者多得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "两个初级试验小组接受手术前德克萨梅萨松",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "在初级试验中记录的所有不良事件都与肌肉和骨骼系统有关,这在次级试验中并非如此。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "初级试验的1号和2号小组以相同的频率接收相同的CUDC-101剂量,唯一的区别是1号小组每周接收一次PD-0332991。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "在二级试验中比在初级试验中有更多的疮和腹泻病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级试验的两群群体在整个试验中以相同的频率接受相同的Docetaxel、Doxorubicin和Cyclophosphamide剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "初级试验的1和2团体遵循相同的节奏呼吸指导CD,但2团体每天练习两次,每周接受抗肿瘤化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "即使患者满足了初级试验的所有排除和纳入标准,最终的纳入决定将由患者首先做亲属。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "患有严重失眠症的患者均被排除在初级和次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            6
        ]
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "初级试验的Bevacizumab群体的结果比Bevacizumab + Capecitabine群体更好。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "初级试验中 ER 阳性 Luminal B 组的 11% 多名参与者显示增长因子签名下降,而不是三消极组",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "一个32岁的患者具有历史学验证的第三阶段乳腺癌诊断,绝对中性细胞数为1807/≈íL,血小板数为110034/≈íL,血糖水平为90g/l,预期寿命超过8个月,可以参加初级和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            10,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3,
            4,
            7,
            8,
            9
        ]
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "初级试验的1或2群体中的任何患者都没有显示出可辨别的40个被评估基因的表达模式。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "患有肺病史的患者不能参加二级试验,目前有乳房植入物的患者不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            20
        ],
        "Secondary_evidence_index": [
            12
        ]
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "在过去的2个月内患有肺动脉疮的患者被排除在初级试验中,但根据研究人员的决定可能有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "二级试验对所有参与者都有相同的包括/排除标准,而初级试验有两套包括标准,一对18～50岁年龄组和一对50岁以上年龄组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "二次试验的组合2的结果比初次试验的组合2的结果更好。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            7,
            16
        ]
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "初级试验的结果表明,手臂A干预的总体响应率比安慰剂手臂好,此外,在次级试验中,Denosumab群体比Zoledronic Acid群体有更好的第一次在试验上的SRE时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "初级试验使用局部干预措施,而次级试验测试一种吸入干预措施。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "总共有两名初级试验的患者患有剂量限制性毒性发病率,两者均来自2组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "初级试验和次级试验在他们的群体中记录了相同数量的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "初级试验中的干预1由IV管理,二级试验中的所有干预药物均可口服。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "在过去一个月内接受器官移植的患者将被排除在初级试验中,但可能有资格参加二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "Sunitinib 每日口服,在整个研究期间在初级试验中给每个患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "初级试验的呼吸介入组的患者平均比快速、浅呼吸组的患者患有更多的治疗突发不良事件和严重治疗突发不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "18岁或19岁以上的女性有资格参加次审,但需要等待1至2年才能参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "少于一半的初级试验参与者在高剂量化疗后出现了循环肿瘤细胞的减少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "初级试验中的患者将在整个试验期间服用更高的阿尔法脂酸剂量,而次级试验的1组患者在整个试验期间服用相同的Necitumumab剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "初级试验的1和2群体之间的区别在于,1群体每天服用25mg至37,5mg的苏尼提尼布,而2群体每天服用10mg/kg的贝瓦西苏马布。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "所有初级试验候选人必须具有HER2阳性肿瘤,由IHC3+确认,以及需要大量的帮助和频繁的医疗护理",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "初级试验的结果表明,手臂A干预提供了最佳的总体响应率,此外,在次级试验中,Denosumab群体比Zoledronic Acid群体有较差的第一次在试验上的SRE时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "NUT中线癌症或耐性前列腺癌的患者,由荧光在现场混合化或炎症性乳腺癌确定,既有资格参加初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "初级试验的参与者接受整个乳房辐射疗法,并在二级试验的两群接受500毫克的Fulvestrant在一个药丸形式,以服用BID。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "二级试验和初级试验中的几名患者患有肿瘤锂症候群",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "在初级试验中有更多的肺炎和一般身体健康恶化病例,而不是在次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "初级试验的1组参与者中没有一个发现有损伤,而二级试验的1组的95%以上的颗粒带有辐射皮肤炎和过度颜色。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "初级试验的所有参与者都经历了认知功能的恶化,特别是卵巢功能抑制组的参与者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "在初级试验中,至少有一名接受GTx-024 1mg治疗的患者获得了超过10公斤的瘦体重。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "在初级试验中接受安慰剂干预的患者比接受Aprepitant的患者有两倍的可能性出现艾梅西。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "吸烟者被排除在初级试验中,但如果他们每天喝不到5杯酒精饮料,他们可能有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "二级试验使用疼痛作为物理疗法的有效性衡量,而初级试验研究硫酸盐补充剂对尿液中的酸盐浓度的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "主要试验1组中的大多数患者遭受了不良事件,而2组则相反。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "在初级试验和次级试验中至少有1例感染",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "在初级试验和次级试验的患者群体中没有观察到肠道障碍或疮事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "二级试验的患者比初级试验的患者更频繁地患有贫血、肺炎和焦虑症,但初级试验记录了更多的发烧感染病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "初级试验的干预第一和第二之间的区别是,干预1使用pIHGC,干预2使用Stantdard GP。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "即使患者满足初级试验的所有排除和纳入标准,将由进行试验的医疗保健专业人员做出最终的纳入决定。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "来自初级试验的Ketorolac 30 mg组的96名参与者经历了无复发生存,而来自NaCl 0.9% 3mL组的67名参与者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "一个32岁的患者具有历史学验证的第三阶段乳腺癌诊断,绝对中性细胞数为1807/≈íL,血小板数为79000/≈íL,血糖水平为90g/l,预期寿命超过8个月,可以参加初级和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            10,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3,
            4,
            7,
            8,
            9
        ]
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "初级试验将其干预进行分语言,而次级试验将其进行口头。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "在初级试验的1组中记录了几例贫血和发烧性中微波尼亚,但0例 Pancytopenia。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "初级试验的干预1和2之间的唯一区别在于,与小组2相比,他们每月的注射中接受了0.7mg的Durva。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "阿尔茨海默病患者不符合初级试验的条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "初级试验 Paclitaxel Plus Bevacizumab Plus Gemcitabine 组的 ORR 比 Paclitaxel Plus Bevacizumab 组更好,并且有更多参与者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "初级试验要求患者每月服用120毫克皮下注射的Denosumab,二级试验不需要注射,而使用淋巴。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "二级试验和初级试验之间唯一共享的包括/排除标准是提供书面知情同意的能力。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "初级试验的LBH589与卡佩西塔宾群体的结果比LBH589和拉帕蒂尼布群体的结果更差",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "初级试验中有一个精神病不良事件,影响不到10%的患者",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "二级试验中最常见的不良事件是贫血,初级试验中没有记录AE。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "二级试验中记录的患者比初级试验的患者多得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "任何日本公民都可以参加初审或次审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67
        ]
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "贫血病患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "在初级试验中记录的唯一AE是胃炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "在初级试验中,哮喘较为常见,而Pneumocystis jirovecii肺炎在次级试验中更常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "一名成年患者在过去3年内被诊断患有散发性甲状腺肺病,将被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            22
        ]
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "曾經進行過四期BC的母乳切除手術的婦女可能仍然有資格參加二級試驗或初級試驗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "初级试验和次级试验的候选人必须符合基准绩效状态,每个试验使用不同的绩效状态分数系统。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "初级试验的参与者服用7种不同类型的药物,必须接受手术,而二级试验的参与者只接受两种不同的药物,不需要接受任何手术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "初级试验中的两种干预措施包括拉斯图苏马布",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "患有新诊断的局部先进乳腺癌的女性,确认为ER+考虑进行乳房切除,有资格参加初级试验和次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "在初级试验中,不到5%的患者患有Aes",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "被诊断为乳腺癌的患者可能符合初级试验和次级试验的所有研究组的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "没有一个初级试验候选人必须作为干预的一部分进行定期锻炼。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "初级试验是测试不同辐射疗法对其研究组的影响,而次级试验是在其研究组中测试相同治疗的不同剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "初级试验中观察到 0 个不良事件,二级试验中没有任何不良事件影响超过 30% 的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "二级试验中的干预时间比初级试验中详细的干预时间长15周。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "只有初级试验的1组将查看教育DVD作为干预的一部分",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "具有 histologically 或 cytologically 确认的乳腺中转移和/或先进的固体肿瘤的患者有资格参加初级试验的第 1 阶段和次级试验的所有群体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "在初级试验和次级试验的患者群体中共有3例疮。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "患有临床检查和超声波测量半径3毫米的初级肿瘤的患者可以参加初级和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "关于不同干预措施的MTD的初级试验和次级试验报告",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "病理上肥胖的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "初级试验患者接受的放射治疗剂量比二级试验参与者高",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "初级试验有一个试验组和一个安慰剂组,二级试验有2个试验组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "参与者必须对AI治疗和 mirtazapine具有抵抗力,才能参加初级试验,但这不需要被纳入次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "原始试验的安慰剂干预和Allo-MSCs干预以相同的剂量通过跨内心脏注射进行。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "二级试验对所有参与者具有相同的纳入/排除标准,而初级试验对不同研究组有两套纳入标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "没有死亡或住院在初级试验的队列2",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "两个乳房中可测量的肿瘤的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ]
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "每位初级试验的患者都需要在放射疗法期间每天吞下1胶囊Vorinostat。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "儿童不能参加初审,但不被明确排除在次审中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "初级试验的干预1和干预2之间的区别在于,干预1比干预2使用高剂量的放射性Tc99M硫合物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "在初级试验中记录的总不良事件和不良事件类型少于二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "初级试验的1和2群体之间的区别在于,1群体每天服用25mg Sunitinib,而2群体每天服用90mg/m^2 Paclitaxel。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "患者在过去6个月内可能没有腹部结膜、胃肠道穿孔、心脏病发作(MI),中风、过渡性结核病发作、内腹部断层或显著精神疾病的历史,如果他们想参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            11,
            19
        ]
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "二级试验研究组的候选人每周接受皮下(SC)注射,而初级试验参与者不接受任何注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "候选人必须在参加初级试验之前进行乳腺检查,这在次级试验中不需要。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "任何性别的患者都可以参加初级试验的两阶段,如果他们有 ER 负性乳腺癌的证据。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10,
            11,
            12,
            14,
            15
        ]
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "女性患有 claustrophobia 和骨质疏松症或不符合初级试验或次级试验的资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3
        ],
        "Secondary_evidence_index": [
            2,
            9
        ]
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "所有为初级试验组1记录的Aes都与心理健康有关",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9,
            10,
            11
        ]
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "具有可重置非小细胞肺癌或小细胞肺癌的 histologically / cytologically确认的诊断的患者有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32
        ]
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "初级试验的1组接受手术前 dexametazone,而2组在手术后2小时接受 dexametazone。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "孕育能力的女性和性活跃的生育男性有资格参加初级试验,但他们需要在整个研究期间承诺弃权。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            20,
            21,
            22,
            23
        ]
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "初级试验有1个试验组和1个安慰剂组,次级试验有1个试验组和1个控制组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "在初级试验和次级试验的患者群中最常见的不良事件是Syncope,在初级试验中的25%的患者中发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "没有心理健康,体重,年龄,卡诺夫斯基/ECOG分数或以前的治疗条件需要满足才能符合初级试验的条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "在初级试验和次级试验中没有记录心脏或精神病AES。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "在初级试验中,Suramin 和 Paclitaxel 都给所有患者,而次级试验干预部分没有描述哪些药物要服用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "初级试验的1和2组患者接受相同的放射治疗剂量,所有患者都接受SPECT扫描。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "对初级试验参与者的肝功能没有条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "在初级试验中记录了更多的心跳、心脏发出和腹痛,而不是在次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "初级试验干预部分不概述治疗周期或治疗的任何描述",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "在初级试验或次级试验中没有发生意外死亡或住院,唯一记录的AEs是3例淋巴瘤。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "初级试验的群体1的参与者与肺炎疫苗接种,群体2的参与者与流感疫苗接种。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "Hypokalemic患者被排除在初级试验中,但可能有资格参加二级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel 仅用于初级试验的 1 组干预,而 2 组服用 fulvestrant。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "初级试验的参与者在整个研究期间接受了4种不同的药物,最大剂量为100mg/m^2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "无论是初级试验的群体在干预中都没有收到任何咨询,风险评估或CBT。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "初级试验对其2个阶段使用单独的包括和排除标准,而次级试验对健康和癌症患者使用单独的标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "在初级试验和次级试验中,在不良事件中记录了10多起死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "乳腺肿瘤直径 0.2-0.8 厘米,确认 HR 阳性和 her2 阳性状态的患者可参加初级和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ]
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "在二级试验中比在初级试验中有更多的疮和Clostridium difficile结肠炎病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "在初级试验的两组中,超过42名患者在手术后大约7个月后出现了乳房和轴心淋巴结的病理完整反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "所有符合二级试验资格的患者也符合初级试验资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "没有意外死亡或住院,发生在初级或次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "初级试验的尼拉提尼布组的iDFS率低于安慰剂组",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "初级试验的1和2组遵循相同的节奏呼吸指令CD,但2组每天练习两次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "平均而言,初级试验中的两个群体都经历了认知功能的恶化,但并非所有患者都有这种情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "初级试验1组中超过50%的患者在接受Aprepitant、Dexamethasone、Cytoxan 和 Kytril 治疗后出现急性呕吐。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "二级试验的干预时间比初级试验的干预时间长3倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "初级试验和次级试验中有 0 例发烧性中风或胆症",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "不能测量转移的患者,或者癌症没有扩散到身体其他部位的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "初级试验中只有2名患者没有复发性生存率",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "初级试验中有几种精神病不良事件,包括饮食障碍和精神分裂症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "NUT中线癌症的患者,由荧光在现场混合,或炎症性乳腺癌确定,既有资格参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "初级试验和次级试验的候选人必须达到基线性能状态,初级试验的基线为 Karnofsky 得分 >70,而次级试验的基线为 Karnofsky 得分 >55。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "患有对特拉斯图苏的严重麻醉反应的患者不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17
        ]
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "在初级或次级试验中,没有患者患有少于3种不同的AE。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "无论是二级试验还是初级试验都没有使用与治疗新兴AES的参与者数量作为他们的研究的结果衡量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "初级试验中没有记录过AES的患者,而二级试验中的每个患者至少经历了一次不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "初级试验使用Lenalidomide的剂量高于介入1中的次级试验使用Lapatinib。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "初级试验报告了在两个群体中共156名患者的几个月进展时间,另一方面,二级试验报告了经历客观反应的患者数量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "在初级试验中记录的口腔粘膜炎、膀胱感染和疮事件的病例多于二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "初级试验不测试任何基于药物的治疗方法,而次级试验测试两种不同的药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "初级试验中的5名患者经历了3次或更多不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "所有初级试验的患者每3周至少服用20mg的MCS110,每2周服用130mg以上的PDR001.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "患有本地恶性管道癌症和无控高血压的患者有资格参加二级试验,但被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            12
        ]
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "初级试验的 1 组服用 ALT-801 少于 2 组服用 0.035 mg",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "没有一群初级试验在干预中接受任何药物,放射治疗或CBT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "初级试验候选人接受的每周MM-121和Paclitaxel比1组的候选人少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "总共有3例Astenia病例和5例Pyrexia病例在初级试验和次级试验的患者群体中记录。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "主要试验干预部分剂量不描述施用方法,剂量或周期。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "在初级试验中,一些正常维生素D水平的患者显示了40个被评估的基因的表达模式。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "曾經進行過乳房切除手術的婦女可能仍然有資格參加二級試驗或初級試驗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "二级试验记录了11个Aes比初级试验更多",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "可测量的双边乳腺癌患者有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "在初级试验和次级试验的Aes中记录了几起肿胀,低温和混乱的情况。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "孕育能力的女性和性活跃的生育男性有资格参加初级试验,但他们必须满足一些额外的要求。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            20,
            21,
            22,
            23
        ]
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "对初级试验参与者的预期寿命、怀孕或年龄没有任何条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "36.36%的初级试验患者经历了血液比利卢宾水平的增加。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "在二级试验中观察到的唯一类型的Aes是眼皮肿瘤和胸痛,在初级试验中没有Aes记录。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "初级试验对其2个阶段使用单独的包括和排除标准,而次级试验对所有参与者使用相同的标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "初级试验中达洛图苏马布20mg/kg组的参与者增加49,2% 显示增长因子签名减少,而不是三重负数组",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "初级试验的参与者接受整个乳房辐射治疗,并在二级试验的两群接受肌肉注射以及药物口服。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "在初级试验中,不到10名患者患有AES",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "初级试验的参与者比次级试验的参与者多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "性别不是决定初审或次审资格的因素",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "初级试验和次级试验对其参与者没有记录不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "初级试验中的25%的患者患有增加的 pleural effusion 和快速的疾病进展",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel 在任何一项主要试验干预措施中都没有使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "初级试验报告了在两群群中共156名患者的日期进展时间,另一方面,二级试验报告了患者经历客观反应的百分比",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "初级试验中的所有感染和发烧病例为1组患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "初级试验中的患者将需要接受几次注射",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Perjeta 用于二级试验的两组,但在初级试验中根本没有应用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "胆症是初级试验参与者比二级试验参与者常见的两倍",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "初级试验的干预包括一个药物,ZD1839,而次级试验的干预需要至少3种不同的药物,包括Zoledronic酸,Samarium-153和Pegfilgrastim。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "诊断为 CCND1 放大、CDK4/6 突变、CCND2 放大的肿瘤的患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "在初级试验中, placebo 干预和 Memantine 干预在同一时间内以相同的频率进行。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "所有在初级试验中用GTx-024 1mg治疗的患者在4个月期间获得了瘦体重",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "没有二级试验或初级试验使用MYMOP分数的变化作为他们的研究的结果衡量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "非洲裔美国患者可以参加初级试验,但他们必须在德克萨斯州逗留研究期间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "初级试验和次级试验都使用pCR作为其结果测量,初级试验的两个群体之间的结果差异很小,而在次级试验中,Arm 2的结果比Arm 1更差,因为Arm 2患者的比率更高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "重复性恶性疾病,格拉夫特对宿主疾病,感染,改变精神状态和散发性状出血在初级试验的不良事件中比在次级试验中更常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "初级试验的1组参与者中没有发现有损伤,二级试验的1组的90%以上的颗粒带有辐射性皮肤炎和过度颜色。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "在初级和次级试验中,有0个不良事件发生在超过1%的参与者中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "初级试验结果报告疼痛强度的变化,二级试验测量了脊椎骨质矿物密度(BMD)从基线到9个月的变化",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "初级试验和次级试验在其干预中不使用相同的药物,剂量或施用频率,但它们都使用静脉注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级试验中,有3倍的肝毒性病例,因为有高血压和胰腺切除症的病例",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "被诊断为激素和/或 progesterone 受体阳性 stadium 4 入侵性乳腺癌的患者,并正在考虑人工智能疗法,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "激光辅助荧光学和侧线射线切割用于初级试验中的两种干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "初级试验中没有两名患者经历过相同类型的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "初级试验的Bevacizumab群体的疾病进展或死亡的发病率比Bevacizumab + Capecitabine群体高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "初级试验和次级试验中有 0 起不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "在初级试验中记录的绝大多数不良事件与血液和骨髓有关,这不是二级试验的情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "在HER2初级乳腺癌的初级试验参与者中,13%接受HER2靶向的PET/CT治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "placebo 干预和初级试验的 Allo-MSCs 干预以相同的剂量通过单一的跨内心脏注射进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验的参与者在第1天、第8天和第15天接受了与sargramostim(GM-CSF)ID混合的HER2/neu疫苗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "一名20岁的女性患者患有新诊断的ER阳性,HER2负的乳腺癌,可能有资格参加二级试验和初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "初级试验对 LBH589 和 Lapatinib 群体没有报告结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "初级试验的干预1中的Zoledronic acid剂量是二级试验的干预1中使用的Denosumab剂量的12倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "两个初级试验试验组将接受相同的18F-FDG和18F-FPPRGD2分子排放扫描 /计算机扫描(PET / CT)成像程序。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "儿童和青少年不符合初级试验的条件,因为他们不符合身高要求,但他们不被明确排除在二级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "初级试验中观察到 0 个不良事件,二级试验中没有任何不良事件影响超过 30% 的患者,除了皮肤感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "参与者必须对人工智能疗法有抵抗力才能参加初级试验,但这不需要被纳入二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "18岁以上的女性癌症患者可以参加初级试验,不论种族、种族或癌症类型,但对于二级试验,他们必须有BRCA+乳腺癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "二级试验和初级试验都使用用CogState衡量的客观认知功能分数作为其衡量单位。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "初级试验的群体2的参与者比群体1的参与者多7人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            21
        ]
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "在初级试验中有有限数量的可用场所为诊断为具有克拉斯或BRAF突变的转移性结肠癌的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "二级试验在其患者群体中记录的总不良事件略高于初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "初级试验中的所有AE类型影响不到10%的患者",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes没有被记录在初审或次审中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "在初级试验中,只有4种不同类型的不良事件影响患者,所有这些都发生在2组中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "性别不是在初级试验中资格的决定因素,但只有女性患者有资格参加二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "在初级试验中,没有接受局部水晶治疗的患者的症状比接受局部水晶治疗的患者更糟。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "二级试验和初级试验之间共有 0 个包含/排除标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "初级试验 Paclitaxel Plus Bevacizumab Plus Gemcitabine 组的 ORR 比 Paclitaxel Plus Bevacizumab 组更好",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "针灸 初级试验中的患者在他们的淋巴肿瘤中看到更好的变化,而不是等候名单上的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "主要试验和次试验的患者群体中最常见的不良事件是Syncope。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "患者的国籍、种族、体重或性别不会影响其参加初级或次级试验的资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "初级试验使用激素干预,二级试验测试针灸干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "初级试验和次级试验在其结果中评估不同患者特征。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "参与初级试验的患者每天服用口服药物两次,持续一个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "初级试验中的 Ketorolac 30 mg 组与 NaCl 0.9% 3mL 组相比,没有复发的存活率为 -6.4%",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "初级试验中的 13 名参与者接受了 Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH合并疫苗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "目前参加二级试验的任何患者也将有资格参加初级试验,因为他们具有相同的纳入标准",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "初级试验中的安慰剂和Trabectedin干预剂以相同的方式施用,但在不同的日子。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "二级试验使用肌肉增量作为物理疗法的有效性衡量,而初级试验研究硫酮补充剂对尿液中的酸酸浓度的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "初级试验和次级试验不测试相同的药物",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "主要试验干预部分需要手术和成像程序。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "具有 histologically 记录的转移性 SCBC 的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "二级试验和初级试验报告来自一个患者群体的结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "在过去3年内被诊断为ILD/DPLD的成年患者,预期寿命为6个月,可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            19,
            22
        ]
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "18岁的人被排除在二级试验中,但初级试验没有指定参与的年龄范围。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "初级试验的两组接受了相同的Abraxane剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "初级试验中的所有感染和感染病例为1组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "二级试验或初级试验不使用cm、参与者数或时间单位作为其衡量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "在初级试验中,不服用帕克利塔克尔的患者的症状比服用帕克利塔克尔的患者更糟。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "在初级试验的1组中记录了1例贫血和发烧性中毒,但没有Pancytopenia的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "初级试验组1和组2的患者接受相同的放射治疗剂量,但组1的干预持续两周。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "参加初审的没有人遭受UTI",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "初级试验和次级试验都给他们的病人群注射了循环磷酸胺,帕克利塔克尔和佩格菲尔格拉斯蒂姆。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "初级试验的 1 组接受了与 2 组相同的 Cetuximab 剂量,但进行了额外的协作护理干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "18岁以上的女性癌症患者可以参加初级试验,不论种族或种族或癌症类型,但对于二级试验,他们必须有 Her2/neu+乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "患有临床检查和超声波测量直径33毫米的初级肿瘤的患者可以参加初级和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "二级试验和初级试验在其结果中使用不同的衡量单位,用于同一结果的测量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            9
        ]
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "二级试验和初级试验使用相同的衡量单位报告其结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "一名患有新诊断的PR阳性,HER2阳性乳腺癌的年轻女孩可能有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "初级试验干预是局部进行的,而次级试验干预是通过注入静脉的针或管进行的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "初级试验的两组接受了相同的Abraxane和Carboplatin剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "平均而言,初级试验中的患者存活超过2年,但至少两个群体中的一个患者在不到2年内死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "具有直径100毫米的TNBC肿瘤的患者有资格参加初级和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ]
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "初级试验对其患者群体仅记录了一次不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "病理上肥胖的患者可能有资格参加初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "所有初级试验参与者获得的ALT-801剂量高于二级试验参与者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "二级试验和初级试验中的大多数患者没有发生任何不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "在初级试验中记录的口腔粘膜炎、癫痫发作和疮事件的病例多于二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "初级试验的1组注射Fluciclatide,而次级试验的1组注射标准剂量的氯化素。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "初级试验的干预1和2之间的唯一区别在于,与小组2相比,小组1在每两周的IV注射中接受了0.7mg/kg较少的Durva。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "初级试验的参与者通过皮下注射服用7种不同类型的药物,必须接受手术,而二级试验的参与者只接受两种不同的药物和几种不同的成像扫描",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "初级试验干预部分不概述治疗周期或辐射剂量的描述。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "平均而言,初级试验的患者存活超过2年,每个群体的50多名患者存活超过24个月",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "初级试验中97%的患者没有出现任何不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "二级试验和初级试验至少具有一个包含标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "在初级试验的两组中,有0例高血压、脱水和失眠",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "初级试验小组中的一半接受任何侵入性手术或Neratinib",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "任何癌症患者被诊断出患有纤维肌痛,症综合征或贫血都不能符合初级试验和次级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "重复性恶性疾病,格拉夫特对宿主疾病,贫血,心力衰竭和散发性状出血在初级试验的不良事件中比在次级试验中更常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "二级试验组2中记录了1例疹病例,但二级试验组1和初级试验中没有例子。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "初级试验的两组记录 0 Aes",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "初级试验中25%的群组2患者患有增加的肺部排泄",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ]
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "患者的国籍、种族、精神病状况或性别不会影响其参加初级或次级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12
        ],
        "Secondary_evidence_index": [
            34
        ]
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "二级试验候选人必须完全无能力参加,而这不需要被录取到初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "在初级试验中的1组不良事件的患者比在初级试验中的2组不良事件的患者多出4。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "二级试验和初级试验具有完全无关的结果测量,但相同的干预",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "无论是二级试验还是初级试验都没有衡量其研究中有临床效益的参与者的百分比(使用(RECIST)标准)",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "二级试验的群体2中的患者比初级试验的群体2中的患者多得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            7,
            16
        ]
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "初级试验2组中超过50%的患者在接受Aprepitant、Dexamethasone、Cytoxan 和 Kytril 治疗后出现急性呕吐。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "初级试验的参与者接受Pembrolizumab的频率是二级试验的参与者接受Sunitinib的频率的两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "参与初级试验的患者每天服用100mg/m2的口服拉帕提尼布,持续一个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "初级试验和次级试验评估具有主要利益的不良事件的参与者的百分比(AEPI)",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "在初级试验的两组中,有0例高血压、肿胀和失眠",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "在初级试验中,患者更常见的是心脏泄漏,在次级试验中更常见的是角膜沉积。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "初级试验报告了研究中分析的参与者总数,但没有报告每个群体的参与者总数。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            21
        ]
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "初级试验不测试任何基于药物的治疗方法,而次级试验测试一种基于药物的治疗方法的不同剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "雌激素负性、 progesterone负性和HER2肿瘤的乳腺癌患者有资格参加初级试验的所有群体",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "初级试验的候选人必须患有乳腺癌并需要激素治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2
        ]
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "初级试验的结果报告延迟恶心的严重性在一个范围内1 - 7和次级试验测量从基线到9个月骨矿物密度(BMD)的脊椎的变化",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "初级试验中的 AZD0530 175 mg 组的初级肿瘤直径比 Zoledronic Acid 4 mg 组减少得更大。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "患有TX NX MX、T0 NX M0或T1 N1 M1肿瘤的患者有资格参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "初级试验的候选人必须有结肠癌,并且对以前的荷尔蒙治疗没有反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2
        ]
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "无论是初级试验的群体都没有接受alisertib,而二级试验的两个群体都接受了不同的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "候选人必须在参加初级试验之前接受乳房检查,而在次级试验中,患者必须先进行CT扫描和血液检查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "所有初级试验参与者获得的药物剂量低于二级试验参与者",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "一般症状是初级试验中记录的最常见AE",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Arimidex 用于初级试验的两组,但在次级试验中根本没有应用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "初级试验的参与者在整个研究期间接受了4种不同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "初级试验中至少记录了1次胃肠不良事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "在研究入学前一个月内接受过抗肿瘤化疗、安道素、雌激素或 progestagen 治疗的任何患者都被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "初级试验和次级试验在其干预中不使用相同的药物,剂量或施用频率,但它们都使用静脉注射和MRI。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "初级试验的1号群体的剂量少于ALT-801作为2号群体的剂量的一半。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "初级试验的1组没有报告任何AES",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "对初级试验候选人来说,基于华法林的治疗是被禁止的,但他们仍然可能有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            31
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "具有 histologically 确认的第 4 阶段乳腺癌的患者是 ER 阳性,PR 阳性或 HER2/neu 阳性,有资格参加二次试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4
        ]
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "同一比例的患者在初级试验的两个群体中遭受了不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "最长PFS患者在初级试验中生存了3个月,没有疾病进展或死亡",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "在初级试验中记录的任何个别不良事件类型都没有影响超过四分之一的患者群体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "初级试验是评估患有治疗相关不良事件的患者数量,而次级试验测量其患者的平均睡眠时间为小时。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "初级试验的1组患者的不良事件比2组的患者多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "病态肥胖和孕期患者可能有资格参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "初级试验中的大多数患者在24周前获得了完整的反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "初级试验中的两种干预措施都包括相同的帕拉普拉丁剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "患有严重失眠和精神分裂症的患者均被排除在初级和次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            6
        ]
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "初级试验和次级试验的干预措施都要求患者每周服用4-Demethyl-4-cholestryloxycarbonylpenclomedine。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "在接受Lapatinib 1000 mg + Nab-Paclitaxel治疗的初级试验中,超过一半的患者出现了确认的完整反应(CR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "在初级试验和次级试验中没有记录心脏或精神病的Aes,但观察到其他几种Aes。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "主要试验干预包括使用Yttrium-90玻璃微球和TheraSpheres的放射性胚胎化,另一方面,次要试验干预包括560mg的ibrutinib和10mg/kg的MEDI4736每日两次一个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "目前吸烟的任何患者都不能参加初级或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "初级试验是在其研究组中测试不同胶的效果,而次级试验是在其研究组中测试相同治疗的不同剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "初级试验或次级试验中的任何一组都没有接受内膜涂层片。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "在研究入学前的2年内接受过抗肿瘤化疗、安原体、雌激素或 progestagen 治疗的任何患者都被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "乳腺癌患者在初级试验中服用了1000mcg/天塔拉索帕里布,而卵巢/腹腔癌患者在初级试验中只服用了25mcg/天塔拉索帕里布。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "初级试验的1群中只有61名宫颈癌患者在干预前进行筛查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "腹泻在初级试验参与者中比二级试验参与者更常见",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ],
        "Secondary_evidence_index": [
            6,
            21
        ]
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "初级试验的1群体中有100.0%遭受某种不良事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "初级试验的粒子接受Epacadostat的频率是Sunitinib的两倍,而次级试验的参与者接受Sunitinib。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "缺乏维生素D的患者被排除在初级试验中,但可能有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "初级试验和次级试验的干预包括完全不同的药物治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "初级试验候选人每周接受的MM-121和帕克利塔克尔比次级试验候选人群1少,但赫塞普丁和多克萨特的剂量较高",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "任何对 cefalosporin、trimethoprim/sulfamethoxazole、levofloxacin 或 celecoxib 过敏的患者都不能参加二次试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "疑似严重不良反应在初级试验的不良事件部分比在次级试验更常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "没有死亡或住院在初级试验的群体2,只有一个病例的疮。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "初级试验的1号群体注射Fluciclatide,而次级试验的1号群体注射IV标准剂量的Chloroquine。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "Suramin 和 Paclitaxel 用于初级试验的所有患者,而次级试验的所有患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "maculo-papular 皮疹是主要试验参与者的常见不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "两个初级试验试验组将接受相同的18F-FDG和18F-FPPRGD2分子排放扫描/计算机扫描(PET/CT)成像程序,除非1组将接受略高剂量的18F-FPPRGD2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "二级试验和初级试验有完全无关的结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "在初级试验中记录的几次Aes发生在1群患者中",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "初级试验要求患者每月服用120毫克皮下注射的Denosumab,二级试验还需要注射,服用0.4至1.0mCi的放射性Tc99M硫。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "初级试验组 2 接受了 0.5ug/kg 的 dexmedetomidine (5 ml),二级试验群体的患者没有接受任何 Dexmedetomidine。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "二级试验研究组的候选人每周接受3次皮下注射(SC),而初级试验参与者在研究开始时只接受一次注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "初级试验用每2周每2周用150毫克口服Pregabalin治疗其患者群体之一,在6周内,二级试验用Depocyt和HD-MTX治疗其患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "总共有两名初级试验的患者患有剂量限制性毒性发病率,每个群体均有1人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "在初级试验的结果中,12周的稳定疾病患者比24周的患者多,但12周或24周的完全反应患者0。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "初级试验和次级试验在他们的患者群体中记录了相同的总数不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "具有 histologically 记录的转移性或不可逆转性 SCBC 的患者被排除在初级试验中,除非他们对 ER 或 PR 或两者都阳性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "初级试验的 1 组服用了与 2 组服用相同的 Cetuximab 剂量,但比 2 组服用减少了 8 mg/kg MM-121。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "在初审和次审中,在不良事件中只记录了一个死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "所有初级试验候选人必须具有HER2阳性肿瘤,经FISH阳性或IHC3+证实",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "在初级试验中,PFS最长的患者属于1组,并且在没有疾病进展或死亡的情况下生存了3个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "以前用加巴宾丁或普雷加巴林治疗将导致排除在二级试验中,但不会排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            12,
            13
        ]
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "初级试验记录的不良事件比二级试验多4次",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "没有X射线,超声波,CT扫描或MRI包括初级试验和次级试验的干预",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "初级试验的1组中,100.0%至少经历了1个危及生命的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "初级试验的 1 组患者接受比 Eribulin 更高的 Cyclophosphamide 剂量,而 2 组患者接受比 Docetaxel 更高的 Cyclophosphamide 剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "初级试验和次级试验正在研究相同的药物,用不同的剂量和不同的结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "初级试验的结果表明,每日Tamoxifen32mg在手术前7天和乳腺癌手术后的14天中平均减少了40%的肿瘤直径。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "初级试验的干预1中的Denosumab剂量是二级试验的干预1中的Tamoxifen剂量的12倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "总体而言,初级试验中的贫血病例比次级试验少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            17
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "在初级试验中有更多的感染、不对称和通胀病例,而不是在次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "在初级试验中,对两群团体报告了相同数量的Aes。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "所有初级试验的患者每3周至少接受20mg的MCS110。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "初级试验和次级试验都给病人的群体施用了循环磷胺。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "与初级试验中的群体的结果没有显著差异,但在次级试验中,反射组和控制组的结果之间发现了一些差异。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "初级试验中的干预措施包括不同的药物,但通过相同的途径进行管理。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "ECOG得分为1的候选人可以参加初级试验和次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "二级试验和初级试验中超过97%的患者没有出现任何不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "初级试验的 A 和 B 组在循环中的同一时刻注射了相同的 LD V935 两次 IM 注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "二级试验记录了比初级试验更多的肠道穿孔11例",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "没有X射线,跨心脏注射,CT扫描或MRI包括初级试验和次级试验的干预",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "二级试验和初级试验使用不同的结果测量和测量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "初级试验的患者将在整个试验期间获得更高的阿尔法脂酸剂量,最多每天3次100mg,而二级试验的1组患者在整个试验期间接受相同的Necitumumab剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "在接受Lapatinib 1000 mg + Nab-Paclitaxel治疗的初级试验中,超过一半的患者出现了确认的完全响应(CR)或确认的部分响应(PR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "雌激素负性乳腺癌患者, progesterone负性和HER2肿瘤有资格参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "大多数初级试验候选人在研究期间患有某种饮食障碍",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7
        ]
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "任何性别的患者都可能有资格参加初级试验的两阶段,如果他们有本地先进和/或转移的固体肿瘤的证据。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "以节奏呼吸干预组的初级试验患者平均每天经历的热波比以快速、浅层呼吸组的患者少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "酒精患者被排除在初级试验中,但如果他们每天喝不到5杯酒精饮料,他们可能有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "患有非小细胞肺癌或小细胞肺癌的 histologically / cytologically确认的诊断的患者有资格参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "初级试验每天两次用150毫克口服Pregabalin治疗其患者群之一,而次级试验则用Depocyt和HD-MTX治疗其患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "经过一个月的TAK-228 PlusTamoxifen治疗,初级试验中的患者在基67表达的细胞百分比下降了10%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "对赫塞普丁的严重抗生素反应的病人或对赫塞普丁治疗的没有反应的病人有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17
        ]
    }
}